Despite a great deal of interest in secondary prevention following an acute coronary syndrome (ACS), with particular attention on antiplatelet and antithrombotic therapies, the standard of care has ...

The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday. Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic ...

Adding the oral anticoagulant rivaroxaban (Xarelto, Janssen) to standard therapy after myocardial infarction (MI) or unstable angina significantly reduced the risk for cardiovascular mortality, data ...

A simpler blood-thinner plan — rivaroxaban alone — can be a strong option for people with atrial fibrillation and stable coronary artery disease, a large age-focused analysis of the AFIRE randomized ...

One winner emerged from a direct comparison of direct oral anticoagulants (DOACs) for patients with acute venous thromboembolism, based on the COBRRA randomized trial. Safety events favored apixaban ...

To receive coverage for Xarelto, a person must be enrolled in a Medicare Part D prescription drug plan or a Medicare Advantage (Part C) plan that includes prescription drug coverage. This article ...

At three months of follow-up, patients hospitalized for a serious heart attack who were treated with the oral blood thinner rivaroxaban for a blood clot in the left ventricle did as well as similar ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In patients with AF requiring anticoagulation, the ...

A new study published in the Journal of the American Medical Association showed that abelacimab, a factor XI inhibitor, ...